Drug-Related Adverse Events of Osteoporosis Therapy
-
-
[1] McMaster University
McMaster University
Canadá
-
[2] University of Toronto
University of Toronto
Canadá
-
- Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 46, Nº. 1, 2017, págs. 181-192
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Postmenopausal osteoporosis is associated with microarchitectural deterioration and increased risk of fracture. Osteoporosis therapy effectively reduces the risk of vertebral, nonvertebral, and hip fracture and has been associated with increased survival. Currently approved treatments for osteoporosis include bisphosphonates, denosumab, selective estrogen receptor modulators, and teriparatide. This article reviews the adverse events of therapy associated with these medical interventions. Hormone replacement therapy is not included, because it is no longer indicated for the treatment of osteoporosis in all countries. Calcitonin and strontium ranelate are also not included, because their indication for osteoporosis has recently been limited or withdrawn.
